Health

Isomorphic Labs closes $5B Series C, setting a biotech record

Isomorphic Labs closed a $5B Series C co-led by Greenoaks and Sequoia, the largest biotech round on record. What it means for digital health in LatAm.

Laboratorio biotech con pantallas de IA y matraces de muestras

Isomorphic Labs closed a $5 billion Series C round on November 17, 2026, co-led by Greenoaks and Sequoia Capital, the largest private raise ever recorded for a biotechnology company, according to BioSpace.

The London-based company, spun out of Google DeepMind in 2021, had raised $2.1 billion in a Series B in May 2026 and has now disclosed at least $7.7 billion across three rounds since March 2025, according to BioSpace. Axios confirmed the amount and the leadership of Greenoaks and Sequoia. Andreessen Horowitz joined as a new investor, alongside Alphabet, Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund. For a health founder in Mexico or Colombia, the round does not compete for their market: it sets the price global capital pays for preclinical risk and establishes the benchmark local funds use to compare their own digital health bets.

The capital is earmarked to scale IsoDDE, the company's drug design engine, and to build foundational biology models. Isomorphic reports positive preclinical results in oncology and immunology, with no disclosed asset and no clinical trial initiated. Its research agreements include Novartis, Eli Lilly and Johnson & Johnson. Demis Hassabis, founder and chief executive, said in the statement that the round allows the company to "accelerate our progress: building foundational biology models". The sector's previous mark was held by Altos Labs, with $3 billion in 2022, according to BioSpace.

The company did not disclose its valuation, according to CNBC. A fund that in 2026 commits $5 billion to a platform with no clinical trials is signaling a willingness to wait for returns of ten years or more, a horizon few venture capital vehicles in Latin America can manage. The data point leaves two questions for the LatAm healthtech operator: which multiples their reference fund uses when the global comparable sits at the preclinical stage, and how pharma agreements get negotiated if that capital accelerates the path to clinical trials.

This article was drafted with the assistance of artificial intelligence from verified sources and reviewed by a human editor before publication.

Sources